Drugs / adrelumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07581795 | Jun 2026 → Feb 2029 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adrelumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581795 ↗ |